Author:
Geier Margaux,Nguyen Jessica,Dhamelincourt Estelle,Babey Hélène,Descourt Renaud,Quéré Gilles,Robinet Gilles,Lucia François,Pacault Mathilde
Reference10 articles.
1. MET exon 14 skipping in NSCLC: a systematic literature review of epidemiology, clinical characteristics, and outcomes;Mazieres;Clin. Lung Cancer,2023
2. MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations;Socinski;JCO Precis Oncol,2021
3. Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review;Cortot;Clin. Lung Cancer,2022
4. Brief report: heterogeneity of acquired resistance mechanisms to osimertinib and savolitinib;Lim;JTO Clin Res Rep,2021
5. 01–60 A novel MET D1246H mutation after progression of EGFR-TKI/MET inhibitor combined therapy in a NSCLC patient with acquired MET amplification;Liang;J. Thorac. Oncol.,2018